Alcon Laboratories, Inc.

Alcon, Inc.

Novartis Ag

Synthelabo

Michael A Kapin

Louis DeSantis, Jr

Robert J Collier, Jr

Mark R Hellberg

Iok-Hou Pang

Louis M Desantis, Jr

Salomon Z Langer

John M Yanni

Daniel A Gamache

Thomas R Dean

Gustav Graff

George E Barnes

David Allen Marsh

Eliot Mark Slovin

Rupa Doshi

Youqin Tian

Bernard Scatton

Michael L Chandler

Compositions and methods for treating disorders of the outer retina with &#x3b2;-adrenoceptor antagonists are disclosed.

Use of beta-adrenoceptor antagonists for the manufacture of a medicament of the treatment of disorders of the outer retina

The present invention is directed to the treatment of disorders involving the accumulation of drusen, such as dry age-related macular degeneration and geographic atrophy via administration of therapeutically effective amounts of at least one monomeric or polymeric cyclodextrin.

Use of cyclodextrins as an active ingredient for treating dry AMD and solubilizing drusen

Compositions and methods for treating disorders of the outer retina with compounds with 5-HTagonist activity are disclosed.

[object Object]

The invention is directed to the use of &#x3b2;-adrenoceptor antagonists for the manufacture of a medicament for the treatment of disorders of the outer retina.

Use of &#x3b2;-adrenoceptor antagonists for the manufacture of a medicament for the treatment of disorders of the outer retina

The use of 3-benzolphenylacetic acids and derivatives, including nepafenac, to treat neurodegenerative retinal disorders is disclosed.

Method of treating neurodegenerative disorders of the retina and optic nerve head

This invention is directed to the use of glutamate antagonists to treat the disorders of outer retina.

Treatment of disorders of the outer retina

Isoquinolinesulfonyl compounds are used in ophthalmic compositions to treat glaucoma or other ischemic-borne ocular disorders such as retinopathies or optic neuropathies. These compounds vasodilate ocular blood vessels, lower IOP and prevent or reduce the progression of visual field loss.

Use of certain isoquinolinesulfonyl compounds for the treatment of glaucoma and ocular ischemia

The invention provides pharmaceutical compositions containing calpain inhibitors and methods of using these calpain inhibitors to prevent or ameliorate ocular neural tissue disease or damage.

Use of calpain inhibitors to treat ocular neural pathology

The present invention relates to the field of ophthalmology. In particular the invention relates to the field of ocular disorders including visual field loss and glaucoma using an isoquinolinesulfonyl compound, which lowers intraocular pressure (IOP) and produces dilation of ocular blood vessels.

The use of polyamine site antagonists in treating ischemic disorders of the retina and optic nerve head are disclosed. Especially preferred are certain 1-phenyl-2-piperidinoalkanol derivatives, such as eliprodil and ifenprodil.

Treatment of ischemic disorders of the retina and optic nerve head

The invention is directed to the use of .omega.-conotoxins for the prevention and treatment of retinal or optic nerve head damage in humans. Compositions and methods are disclosed.

Use of .omega.-conotoxin analogs for treating retinal and optic nerve

Methods for preventing and treating retinal edema with brinzolamide are disclosed.

Treatment of retinal edema with brinzolamide

Polyamine antagonists are found to be effective in preventing or reducing visual field loss associated with glaucoma. Especially preferred are certain 1-phenyl-2-piperidinoalkanol derivatives, such as eliprodil and ifenprodil.

Use of polyamine antagonists for the treatment of glaucoma

The use of certain aliphatic carboxylic acid derivatives to treat persons suffering from retinal or optic nerve head damage is disclosed.

Use of aliphatic carboxylic acid derivatives in ophthalmic disorders

Pharmaceutical compositions useful in ophthalmic surgery are described. The compositions include one or more polyamine antagonists, and are useful for preventing or treating excitotoxicity associated with ophthalmic surgery. Methods of using the compositions in connection with ophthalmic surgical procedures are also described.

Growing community of inventors

Arlington, TX, United States of America

Michael A Kapin